Podcasts about moffit

Mit neuer Energie und Grusel-Laune stürzen Kim und Denise sich in die erste Folge der bereits fünften (!) Staffel von Null Uhr Eins. Zum Auftakt widmen die beiden sich Werken, die generell “unterschätzt” geblieben sind. Kim bringt Guillermo del Toro endlich auf ein repräsentativ-angemessenes Level im Podcast, indem er seinen 2015 erschienenen Film “Crimson Peak” bespricht.  Die eher klassische Geistergeschichte, so Kim, hat die harsche Kritik des Internets nicht verdient, im Gegenteil: “Crimson Peak” ist eine unterhaltsame Anerkennung und Zelebrierung eines fundamentalen Teils des Genres. Denise wiederum feiert Premiere: endlich bringt sie etwas aus der bildenden Kunst mit. Ana Mendieta und ihr Werk “People Looking at Blood, Moffit, Iowa” (1973) ist zwar nicht unterschätzt; der tragische Tod der kubanischen Künstlerin wirft jedoch Fragen auf: Was bedeutet es, als Künstlerin unterschätzt zu werden, und wie hängen posthume Anerkennung und Misogynie zusammen?Achtung!- Es gilt eine Inhaltswarnung zum Thema sexuellen Missbrauch und Vergewaltigung. Zwischen 1:05:02 und 1:05:41 spricht Denise über diese Verbrechen. Zwischen 1:06:10 und 1:06:38 beschreibt Denise detailliert ein Kunstwerk Mendietas, welches diese Taten künstlerisch nachstellt: “Untitled (Rape Scene)“ (1973).Shownotes: https://www.dropbox.com/scl/fi/ah4nzkidiqos44yrvkybr/50-Untersch-tzt-Shownotes.docx?rlkey=451ebisvhwl8c72pi1hdqr5ax&st=gajr0gny&dl=0

Dating has changed—dramatically. From ghosting to breadcrumbing, love bombing to the pressure of “the spark,” navigating modern romance can feel like a minefield. Enter Dr. Kimberly Moffit, renowned relationship therapist and dating expert, here to break it all down. In one of our most requested episodes ever, we dive into dating after divorce, how to know when you're ready to get back out there, the biggest red (and green) flags to watch for, why Gen Z is delaying marriage, and how to actually enjoy dating again—yes, it's possible. Whether you're newly single, divorce-curious, or just burnt out on the apps, this one's for you. Mentioned in the Episode: Hot Couture Perfume by Givenchy A Sony Music Entertainment production. Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Carrie and Melody discuss how to incorporate animal and eco protection into your life in meaningful ways to meet your own life goals, priorities, and interests in big and small ways, syncing up with actions and virtues the world needs from us humans.  Since the beginning of each new year is a time to reassess our own goals and priorities, it seemed a good time to have an In Tune to Nature show that focused on our own personal growth resolutions and how that can synergize with efforts to help other species. This is also a special show because it airs on the radio on our birthday, January 8th, as my co-host and friend Melody Paris and I share the same birthday – just one of the many things we have in common. The agenda for the 1 hour show today is that before we get to some personal growth exercises and self reflections that you our listeners can use to figure out your own best path (inspired by best selling personal growth authors), I thought Melody and I would start by sharing our own path toward incorporating animal and eco issues into our daily lives (over the decades) to see how our own stories and actions might resonate with listeners or spark ideas for you. So it would be good for you to have a way to take notes during this show, and you can pause at times to answer some questions and do some self reflection (on your inner priorities, and what excites you, what you're good at, and what the world needs to protect animals and nature) before we move on to each new topic. My sign-off each show has been “Take care of yourself and others, including other species,” and I literally think that is the meaning of life. And in this anthropocentric (human-centered) culture, I want to make sure we don't leave other species out of that care-taking effort -- with the goal of us shifting our identities and culture toward a biocentric (life-centered) orientation and beginning to see ourselves as part of a broader community as human animal earthlings. So our resolutions/goals can be in improving our mindset and identity as well as in formulating tangible task-oriented goals/achievements. Toward the end of the podcast, Melody and I review the top 20 virtues that humans could embody, from pg 207 in my "Human Animal Earthling Identity" book, so virtue ethics plays a role in this show. The show draws upon books like "Essentialism" by G. McKeown, "Emotional Chaos to Clarity" by P. Moffit, and "Die with Zero" by B. Perkins, and "Oasis Earth" by R. Steiner.   "In Tune to Nature" is a weekly radio show airing Wednesdays at 6:30pm Eastern Time on 89.3FM-Atlanta radio and streaming worldwide on wrfg.org (Radio Free Georgia, a nonprofit indie station). Hosted by me, Carrie Freeman, or Melody Paris. The show's website and action items can be found at https://wrfg.org/in-tune-to-nature/  Please support nonprofit indie media like our Radio Free Georgia station at https://wrfg.org/  Thank you! Take care of yourself and others, including other species. That's the meaning of life! Photo Credit: Carrie Freeman. I took this photo of my hand petting a rescued goat at a sanctuary in Georgia, as part of a Georgia Animal Rights and Protection hands-on volunteer day that Melody helped organize.

Airborne operations were an essential component of the Allied invasion. And since D-Day, the US Army has stood ready to drop airborne forces anywhere in the world at any time. The US Army Golden Knights are America's most proficient parachutists. Led at the time of this recording by Green Beret Lieutenant Colonel Andy Moffit and Command Sergeant Major Adam Breeding, the Golden Knights set the example for airborne insertion onto any drop zone.LTC Moffit and CSM Breeding joined Fran Racioppi from atop the Normandy Resistance Monument in Saint Marie Dumont to discuss just what it means to be Airborne, both in 1944 and today. They shared what it takes to join the Golden Knights, how they maintain standards and why they are always competing for the perfect jump; especially when the eyes of the world are watching. Check out our conversation from the birthplace of modern Special Forces and home to one of the largest airborne drops in history; then head over to our YouTube channel or your favorite podcast platform to catch all our coverage from the 80th Anniversary of D-Day. Follow the Jedburgh Podcast and the Green Beret Foundation on social media and make sure to tune into our first documentary, Unknown Heroes: Behind Enemy Lines at D-Day, the story of Operation Jedburgh available now only on YouTube.HIGHLIGHTS0:00 Introduction2:12 Welcome to Normandy5:03 Golden Knights' mission7:00 Why become a Golden Knight9:05 What is a Golden Knight?12:56 Building A Great Team15:31 Maintaining a High Operational Tempo17:14 Best part of being a Golden Knight18:04 The meaning of Normandy22:20 Future of the Golden Knights27:29 Daily Foundations of SuccessQUOTES“Our mission is to connect America's people to her Army.”“I really had to check my ego at the door.” “Culture is king. Culture is everything.”“It really comes down to how teachable are you.”“It's that healthy level of fear though. That's what keeps them focused.” “We jump from thousands of feet. A good portion of the team is afraid of heights.” The opinions presented on the The Jedburgh Podcast and the Jedburgh Media Channel are the opinions of our guests and creator and host Fran Racioppi. They do not necessarily reflect the opinions of the Green Beret Foundation and the Green Beret Foundation assumes no liability for their accuracy; nor does Green Beret Foundation endorse any political candidate or any political party.

Should existing health care providers have veto power over new providers moving into the community? How does this affect your health care in your community? In this week's edition of The Commonwealth Matters we are joined by Robert Moffit of the Heritage Foundation to discuss and clarify the complex topic of certificate of need reform in Kentucky.  If you would like to interview Richard Nelson, Executive Director of the Commonwealth Policy Center, please email ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠richard@commonwealthpolicy.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Like and Follow us on Facebook: www.facebook.com/commonwealthpolicy Follow us on Twitter: @CPC4Kentucky LinkedIn: Commonwealth Policy Center E-Newsletter: https://www.commonwealthpolicycenter.org/mailing-list/ --- Support this podcast: https://podcasters.spotify.com/pod/show/commonwealth-matters/support

January 11, 2022 - Donna Firman & Jenny Moffit

One of our own Maddox Corcoran made a deep run at the Portland Regional Championships, finishing in 3rd place overall. Maddox will discuss his decklist and provide a tournament report. Nick Moffit joins to discuss his recent Top 8 finish at Portland regional. All this and much more on this week's episode of the Beach Court Podcast! Thanks to Nakama Anime Cafe for being an official sponsor of the Beach Court Podcast!  They offer a traditional Japanese dining experience right here in our backyard of Orange Park, FL. Nakama also has a karaoke bar right next door. Grab some grub and then head next door to sing along some Pokemon songs. Find more details at:https://nakamabar.com/nakama-cafe/ Tell them that Beach Court Podcast sent you :) Follow the Beach Court Podcast Socials: LinkTree: https://linktr.ee/beachcourtpod Follow the Beach Court Podcast crew on Twitter: Eric - https://twitter.com/RidgewayTCG Maddox - https://twitter.com/MaddoxTCG Parker - https://twitter.com/Squint_PTCG #pokemon #pokemontcg #BeachCourtPodcast

In HOUR ONE of OTB, T Bob and Hester discuss Tommy Moffit, their former coach, heading to Texas A&M. This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5595167/advertisement

The Texas native has broadcast from his home state to Germany to Denver, Chicago, Atlanta, and for many years Kansas City, and from Top 40 to Album Rock, with his own unique style that earned him a spot in the Rock and Roll Hall of Fame. Storytelling at its very best!

In this riveting episode, join us as we unravel the captivating stories of two extraordinary individuals—Chris Judd, the iconic football legend and now investor, and Harry Moffit, the battle-tested SAS Team Commander turned Psychologist. Delve into the intricate relationship between career transitions and personal identity, peeling back the layers of ego, embracing change, and the transformative power of sacrifice. Chris Judd, a dual Brownlow Medallist and former West Coast and Carlton captain, stands as a sporting icon, recognised in the Australian Sports Hall of Fame. His career, marked by resilience and leadership, has left an indelible mark on the AFL, solidifying his status as one of the greatest to play the game. Post-retirement, Judd has ventured into the business world with Chris Judd Invest, launching a new equities fund, now embracing new challenges and ensuring he has an impact extending beyond the field. Harry Moffit is an Australian legend, a SAS Team Commander with 11 combat deployments, who embarked on a journey from the intensity of special forces to the nuanced realm of psychology as a Human Performance Expert. As the Managing Director of Stotan Group and the author of the acclaimed 'Eleven Bats, Moffit's expertise extends beyond the battlefield, encompassing decision-making, discipline, and the profound interplay of culture and character. Explore the depths of these compelling stories in the episode as we uncover how these two legends navigated change, confronted ego, and harnessed the power of sacrifice to achieve extraordinary goals. This conversation delves into our life journeys, navigating different stages and the process of moving through preconceived notions of identity. This episode provides valuable lessons for listeners on embracing change, resilience, and personal growth in our daily lives. For more information about our guests: Harry Moffit www.stotangroup.com.au www.harrymoffit.com.au Chris Judd www.chrisjuddinvest.com

In this episode I host Matthew Broberg Moffit, fellow autistic chef and author of "Color, Taste, Texture"*Check out Matthew's book by accessing this link: https://www.penguinrandomhouse.com/books/704923/color-taste-texture-by-matthew-broberg-moffitt/

US healthcare spending is extreme currently at approximately $4.3 trillion.  The single largest payer of healthcare services is Medicare at roughly $900 billion annually or 21% of total healthcare spending.   In this edited volume, recently published by Johns Hopkins University Press, Dr. Moffit along with eleven other contributors including Joe Antos, Douglas Holtz-Eakin, Brian Miller, Mark Pauly and Gail Wilensky, lay out the conservative version of Medicare reform.  In sum, the authors argue federal policymakers reinvent Medicare as a defined contribution or premium support program or at minimum substantially expand the Medicare Advantage program (Medicare Part C), or Medicare coverage provided by private insurance companies.  The interview begins by Dr. Moffit commenting on whether healthcare services can be defined as a market commodity. He discusses the problem of healthcare pricing, measuring for value in healthcare, improving Medicare Advantage benchmarking, remedying Medicare Advantage coding intensity via retrospective risk adjustment and risk transfer pools and competing fee for service Accountability Care Organizations (ACOs) against Medicare Advantage. Dr. Robert Moffit is a Senior Fellow in Domestic Policy Studies at The Heritage Foundation specializing in health care and entitlement programs, moreover Medicare. Dr. Moffit also serves on the Maryland Health Care Commission as an appointee of Gov. Larry Hogan and he is a member of the advisory board of the Buckley School of Public Speaking in Camden, South Carolina. He brings to the reform effort experience as a senior official of the U.S. Department of Health and Human Services (HHS) and the Office of Personnel Management (OPM) during the Reagan administration. Dr. Moffit is a co-author of “Why Obamacare Is Wrong for America,” (Harper Collins, 2011). He was a contributor to “A Time for Governing: Policy Solutions From the Pages of National Affairs” (Encounter Books, 2012) and “Controversial Issues in Social Policy” (Allyn and Bacon, 2003), a university textbook on public policy. He has published in numerous professional and specialty journals among them Health Affairs, Health Systems Review, Harvard Health Policy Review, Inquiry, Journal of Law, Medicine and Ethics, National Affairs, New England Journal of Medicine, Postgraduate Medicine, and Journal of Medicine and Philosophy. His analysis and commentary have been cited or published by The New York Times, The Wall Street Journal, The New York Post, The Washington Post and The Washington Times. He holds a master's degree and a doctorate in Political Science from the University of Arizona. He received his bachelor's degree in Political Science from LaSalle University in Philadelphia. Information on “Modernizing Medicare,” is at: https://www.press.jhu.edu/books/title/12839/modernizing-medicare. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

The Beach Court Podcast team discusses the debacle that was getting to Pittsburg from Florida. Adam Reinhardt talks about his deck choice and Top 8 run for Pittsburgh regional! 2023 Top 16 NA player Nick Moffit joins to discuss his recent Top 10 finish at Pittsburgh regional. All this and much more on this week's episode of the Beach Court Podcast! Thanks to Nakama Anime Cafe for being an official sponsor of the Beach Court Podcast!  November 4th & 5th you can join us at Nakamacon by purchasing your early bird tickets or signing up to be a vendor at: https://linkin.bio/nakamajax?fbclid=PAAaZpIDVzWtjPFBRMXKtQqDfuIIoAg3CD6vHMy3OCQGGnAIeUzlMpdz7jQvY_aem_AcUtBrcAjI-7SX6Eu9fKkVj8k_0SpQW7o-xnKIoWIgVWY589uiAKinGf0207lEgoo4Q They offer a traditional Japanese dining experience right here in our backyard of Orange Park, FL. Nakama also has a karaoke bar right next door. Grab some grub and then head next door to sing along some Pokemon songs. Find more details at:https://nakamabar.com/nakama-cafe/ Tell them that Beach Court Podcast sent you :) Follow the Beach Court Podcast Socials: LinkTree: https://linktr.ee/beachcourtpod Follow the Beach Court Podcast crew on Twitter: Eric - https://twitter.com/eridgeway6590 Maddox - https://twitter.com/MaddoxTCG Parker - https://twitter.com/Squint_PTCG #pokemon #pokemontcg #BeachCourtPodcast

August 30, 2023 - Lt. Jennie Moffit

August 30, 2023 - Lt. Jennie Moffit

Interpreters of the Epistle to the Hebrews have long taught that its author took the view that Jesus canceled the Torah, the Law of Moses, along with all its sacrifices and rituals. However, our guest today, Dr. David Moffitt, has taken a different perspective. He walks us through his intensive study of the concepts of atonement and reconciliation in the Old and New Testaments. He concludes that Hebrews can find its place among other Jewish works of the Second Temple Era, as its author had nothing but respect for Moses and the Torah. – Episode Highlights – • How Dr. David Moffit came to think differently about atonement. • The surprising impact of the resurrection of Jesus on understanding the book of Hebrews. • Understanding Jesus' sacrificial death in light of the Levitical sacrificial system. • What did the slaughter of animals accomplish in the Levitical system? • What was the focal point of Jesus' sacrifice? • What does killing an animal on the altar of the Tabernacle or Temple accomplish? • Understanding the various types of sacrifices and their basic functions. • What is atonement, and why is it necessary? • Does Hebrews 3 eliminate the Levitical system? • Melchizedek, Hebrews 7, and a heavenly priesthood. • Does the book of Hebrews regard the Torah as relevant or authoritative? • How can Jesus be a high priest even though he is not from the tribe of Levi? • Was it Jesus' death or his ascension that accomplished the work of atonement? • What is Dr. David Moffit's next book project? – Related Resources – Rethinking the Atonement by Dr. David Moffit https://www.amazon.com/Rethinking-Atonement-Moffitt/dp/1540966232 Messiah Magazine: messiahmagazine.org First Fruits of Zion: ffoz.org Messiah Podcast is a production of First Fruits of Zion (ffoz.org) in conjunction with Messiah Magazine (messiahmagazine.org). This publication is designed to provide rich substance, meaningful Jewish contexts, cultural understanding of the teaching of Jesus, and the background of modern faith from a Messianic Jewish perspective. Messiah Podcast theme music provided with permission by Joshua Aaron Music (JoshuaAaron.tv). “Cover the Sea” Copyright WorshipinIsrael.com songs 2020. All rights reserved.

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in melanoma, including targeted therapy and the addition of LAG-3 inhibitors to checkpoint therapy, as well as promising checkpoint inhibitors in cutaneous squamous cell carcinoma and Merkel cell carcinoma in advance of the 2023 ASCO Annual Meeting.  TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I'm delighted to welcome my colleague and friend, Dr. Jason Luke. Dr. Luke is an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh's Hillman Cancer Center. He is a very, very well-renowned physician-scientist who has done fundamental work in developmental therapeutics and also in melanoma.  Today, we'll be discussing some key oral abstracts highlighting advances in immunotherapy in the cutaneous malignancy space that will be featured at the 2023 ASCO Annual Meeting.   You will find our full disclosures in the transcript of this episode and the disclosures of all guests on the ASCO Daily News Podcast are available in our transcripts at asco.org/DNpod.  Jason, thank you for coming on the podcast today. Dr. Jason Luke: Well, thanks so much for the opportunity. Dr. Diwakar Davar: So, we will go right ahead into the abstracts and the first one we thought we'd discuss is Abstract 9502, which is the RELATIVITY-047 study, specifically the 2-year results. This is the update. This has also been concurrently published at the New England Journal of Medicine Evidence online. And so in this publication and oral presentation, Hussein Tawbi, Georgina Long, and colleagues are talking about the nivo-rela data in the context of metastatic melanoma. So what is your take on this? What is your take on the data both presented and published and how would you contextualize this for the audience? Dr. Jason Luke: Right, so the RELATIVITY-047 study, as people will remember, randomized treatment-naive patients with metastatic melanoma to either receive nivolumab as standard treatment as a monotherapy or the combination of nivolumab and the anti-LAG-3 antibody relatlimab. And that study reported out a couple of years ago showing the improvement in progression-free survival as the primary endpoint. And at the time we saw that difference was approximately a 6-month absolute difference. And eventually, we saw there was an increase in the overall response rate also, again, approximately on the order of about a 10% change. What was interesting was that the overall survival initially was immature and that was an interesting follow-up point that we wanted to see. So I think what's important in seeing now this 2-year update of these data are the maintenance of the benefit for nivolumab plus relatlimab as compared to nivolumab alone across those measurements of progression-free survival and overall response rate.  Interestingly, the overall survival in the clinical trial actually did not meet the pre-specified threshold for statistical significance. That being said, when you look at the data presented in the Kaplan-Meier plots and you think about the difference, it really does appear that there's a clinically meaningful difference between these 2 groups. And the statistical cut point only missed by about .01. And so this is one of those areas where one wonders whether or not subsequent therapies may have impacted on the overall survival calculation because obviously, patients in this trial had not received ipilimumab or a PD-1 CTLA-4 combination. So the take-home message from me in this data set was that the benefit of nivolumab and relatlimab was sustained over time and there was no suggestion of any late toxicities that might make us concerned.   One advantage of this combination of nivolumab and relatlimab is the dramatically improved side effect profile relative to nivolumab and ipilimumab. So whereas immune-related adverse events that were serious, grade 3-4 is approximately 50% for nivolumab and ipilimumab, in the RELATIVITY-047 study, we see that the incidence of grade 3-4 toxicities for nivolumab and relatlimab is 17.2%, so that's less than half. So that's pretty attractive. And when we think about frontline management of patients, I think these data really support that nivolumab plus relatlimab is a reasonable consideration for some patients. And now I think the future question is really going to be, okay, well then who should get nivolumab and relatlimab versus who should still get nivolumab plus ipilimumab? Obviously, these data do not address that, and I think that that's probably the most important question for metastatic disease that's probably on the horizon. Dr. Diwakar Davar: Thank you, Jason, those are all fantastic points. It is interesting to note that as a result of the data, or really the lack thereof, the combination is actually not being launched in certain countries. So, for example, the German Health Authority, GBA, the Federal Joint Committee in Germany has decided against the acceptance of this agent because it does not accept event-free survival (EFS) as a patient-relevant endpoint. So it's interesting that we have an agent that is now going to be FDA-approved. It's already FDA-approved and available in the United States, but it will not be at least available in Germany and there may be other countries that decide favorably or unfavorably depending on how this OS data is viewed.   So pivoting to another LAG-3 inhibitor in this case fianlimab, we're going to discuss Abstract 9501. So Abstract 9501 essentially is describing a phase II trial that evaluated the LAG-3 inhibitor, fianlimab, along with the anti-PD-1 inhibitor, cemiplimab from Regeneron. The data is slightly different from what we have seen with RELATIVITY-047, the Opdualag combination. So Jason, how would you contextualize the fian-cemi combination in advanced melanoma in the context of what we've seen with RELATIVITY-047? If you could help us with that, please. Dr. Jason Luke: Yeah, absolutely. So before we dive into this specific abstract, it's, like you mentioned, probably useful to just put all of this in context. Targeting LAG-3 as an immunomodulatory approach has actually been in clinic for a decade approximately. And so the relatlimab phase 1 started quite a long time ago. And there was data for nivolumab and relatlimab in PD-1 refractory patients with melanoma that showed not a tremendously obvious level of activity. And so it was thought there that the only place they would see that activity was to go to a frontline randomized phase 2 and then phase 3 trial, as we just discussed.  In contrast to that, given all the data that had come forward about LAG-3 targeting with relatlimab, the group developing fianlimab took a different approach and rather treated a cohort of patients with treatment-naive melanoma to try to get an initial assessment right away of the activity as read out by overall response rate for this PD-1 plus LAG-3 combination, which is cemiplamab plus fianlimab.   And these authors have previously presented data about this combination from cohorts of patients who are treatment-naive who received this combination and described approximately a 64% overall response rate. And that's an impressive number in the treatment-naive setting. There's sort of a tension there to sort of say, well, wait a minute, the response rate in this single-arm study is 64%, but in RELATIVITY-047, the response rate was lower for the LAG-3 combination and I think that's not a fair comparison. We have to realize this is a much smaller group of patients that has the potential to have been somewhat biased towards a better cohort just because of where and when they were recruited to participate in this trial. All the same, I think that number does look impressive and suggest that this combination is active in the frontline.   Specific to this abstract, though, what the authors presented here was to update those previous data and then specifically also to focus on a cohort of patients who are allowed to have had previous treatment in the perioperative setting. So either neoadjuvant or adjuvant therapies. And in a subgroup of patients, they observed that even in the patients that had received adjuvant anti-PD-1 who went on to then progress later, they got actually a similar overall response rate at approximately 60% even in that group. And so I think that that seems like an exciting number as well. One would on first principles think that if patients got an adjuvant anti-PD-1, then a PD-1 LAG-3 combo could be less active. When and how the patients progressed or did not on that adjuvant therapy, however, I think makes a big difference. And given the relatively small sample size of patients that were included in this report, which is on the order of 20-ish patients who were in the previous PD-1 treated adjuvant cohort, I don't know that we can make super broad analyses trying to compare across the development programs.  What I would take from this abstract, however, is that it does appear that this other PD-1 LAG-3 combination cemiplamab plus fianlimab is also very active and certainly deserves to be investigated in similar clinical trial contexts as the nivolumab plus relatlimab combination that we previously discussed. And while it's not specifically stated here, that is happening, there is a frontline phase 3 trial for this combination of fianlimab and cemiplamab as well as adjuvant considerations, also ongoing. Dr. Diwakar Davar: So, thank you. We've seen a lot of LAG-3 data this last 2 months, the phase 2/3a RELATIVITY-020 trial has just been published in the JCO, I encourage people to read that. And so that was the evaluation of nivolumab and relatlimabin the post-PD-1 patient population that Jason alluded to, where the response rate that was observed was 12%. So we've seen a lot of interesting data, a lot of interesting survival data, and now a new potential combination with LAG-3 with fianlimab and cemiplamab from Regeneron. So it'll be a very interesting next couple of years as we see whether or not this new combination, how it shakes up against the established nivu-rela combination, again, albeit with the limitations of cross-trial comparisons and also how it performs against cemiplamab in this ongoing, as you alluded to, ongoing global phase 3 trial.  So, pivoting away from melanoma, now addressing the context of another cutaneous malignancy, a very high-risk one, Merkel cell carcinoma. So, Merkel cell carcinoma for those who are not necessarily treating a lot of this is a very rare and very aggressive cutaneous tumor. It's a neuroendocrine tumor of the skin. It's a cancer that's typically associated more than about 60% of the time with a cancer-causing virus, an oncogenic virus known as a Merkel Cell Polyomavirus.   And in this setting, checkpoint inhibitor therapy has been approved for the last couple of years, initially with a PDL-1 inhibitor, avelumab, and then more recently with a PD-1 inhibitor, pembrolizumab. And, at this point in time, there are three FDA-approved agents that are checkpoint inhibitors that are available for the treatment of this disease.   And CheckMate-358 was essentially a trial of nivolumab plus/minus ipilimumab in the setting of this Merkel cell carcinoma. So, Jason, what are your thoughts on how the addition of ipi did in this setting [in Abstract 9506]?  Dr. Jason Luke: Yeah, so I think this is a really interesting abstract because there's a slightly more context even than what you alluded to there. This study is an open-label, multi-cohort, but single-arm investigation where one cohort of patients received nivolumab alone and the other cohort received ipilimumab. It needs to be buttressed by a previous publication in The Lancet last year by the group at the Moffitt Cancer Center who also did a prospective study looking at nivolumab and ipilimumab. In that previous study that the Moffit group did, they got a response rate of 100%. All patients responded to the combination of nivolumab and ipilimumab in their study and that was quite provocative, suggesting that while anti-PD-1 alone has about a 50% response rate, adding ipi in that scenario then took it to 100. So these data were very much of interest because this could be a confirmatory data set to suggest for this rare tumor that perhaps a combination regimen should be preferred. Of course, one has to remember that adding ipilimumab to anti-PD-1 substantially enhances the toxicity profile. And these patients tend to be elderly that develop this kind of cancer, Merkel cell carcinoma. So that's a rather important caveat.   Just to get to the crux of what happened in this trial. As opposed to the previous Moffit trial, there actually did not appear to be a major increase in the benefit of adding ipilimumab, at least in this trial. Because again, in parallel cohorts, the NIVO monotherapy arm had a 60% response rate, which is roughly a little bit higher, but roughly in line with what we've seen previously. And the response rate to nivolumab plus ipilimumab was 58%. So, I mean basically the same. So, how can it be then, that we have this previous very high-profile publication that says 100% response? Now, we have a second publication that says adding ipi doesn't do anything - that's confusing, and I think it'll be really important to try to look at what were the differences between these two cohorts of patients. Did one of them have higher risk features, greater disease burden, et cetera? We don't really know that just yet, but trying to tease that out will be important.  This data also emphasized, though, the complexity around the dosing of ipilimumab. And in melanoma, we never really figured out what the best dose of ipilimumab was to give either alone or even in combination with a PD-1. And we don't really have time to get into all of it right away here, but there are multiple studies in melanoma that would suggest that giving ipi on an every 3-week dosing schedule is superior to giving it on a 6-week dosing schedule. In this study, they did use the 6-week dosing schedule. So, whether or not that could have made a difference, I guess, is unknown. But I would notice that in the previous Moffitt trial, they also used that six-week dosing schedule. This one's a head-scratcher for why did these data not confirm a previous data set? But for the time being, I think this emphasizes that PD-1 monotherapy really is the standard approach that should be considered for patients with metastatic Merkel cell carcinoma.  Dr. Diwakar Davar: That's great, Jason. And so, again, it's a very tough patient population. These are very rare patients. The Moffitt trial that Jason alluded to essentially was a trial that had in each arm, there were approximately 25 patients, of which 13, or between 11 to 13 patients were actually checkpoint inhibitor naive, wherein the dramatic 100% response rate was seen. And this is a trial where at least in this update, we've got about 25 patients in nivo monotherapy, I mean in 43 patients. And so, in a disease that is thought to be extraordinarily sensitive to checkpoint inhibitor immunotherapy because of the role of the virus and the high TMB that it's associated with, it is very interesting that the addition of an additional checkpoint inhibitor did not appear to improve outcomes. But as you alluded to multiple reasons, but we don't know how it's going to shake out. Next, Abstract 9507 and this is a very interesting trial known as the MATISSE trial. So, in the context of cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma is a relatively not uncommon cancer, primarily seen in older cancer patients, particularly a little bit more common in men. And in this setting, we've got checkpoint inhibitor therapy that is FDA-approved, at least two of which are FDA-approved right now, pembrolizumab and cemiplamab both were approved in the advanced cancer setting. And we do know that because of the extraordinarily high tumor mutation burden associated with cutaneous squamous cell carcinoma, checkpoint inhibitor therapy has got a very dramatic effect. Response rates are between 35% to 42% with pembrolizumab and 40% to 50% with cemiplamab, depending on whether or not one looks at the relapsed metastatic or the locally advanced patient populations.  And interestingly, much like we've seen with melanoma, we have migrated the use of this therapy early in the lines of patients, particularly in the setting of perioperative therapy. So, Jason, how would you contextualize the results of the MATISSE trial in relation to the existing and known data from several of our colleagues regarding the role of what checkpoint inhibitor therapy is doing in terms of organ preservation?  Dr. Jason Luke: Yeah, and I think this is an area of tremendous excitement. And as you were alluding to, the activity of anti-PD-1 really was transformative in this disease, which really can be a disfiguring and locally destructive disease. And with that activity for unresectable disease, last year, near the end of the year, there was a first report of a large neo-adjuvant clinical trial in cutaneous squamous which showed really outstanding results in terms of improving surgery and pathologic complete response using anti-PD-1 in that setting. And for this trial, this was a trial done in Europe; they took a similar tact of trying to think about giving anti-PD-1 or anti-PD-1 with anti-CTLA-4 with ipilimumab in that neoadjuvant period to see whether or not they could reduce the use of extensive surgery and/or radiation therapy.  The short version is they were able to do that. And so they described 40% of patients with single-agent anti-PD-1 and 53% of patients who received a combination having major pathologic response to treatment. And this was so much so that 10 of the patients who had pathologic responses actually withdrew their consent to go on to have surgery because they decided that they had had such a good effect of the immunotherapy, they weren't willing to put themselves through what was going to be a very difficult surgery. And I think that speaks to the upside potential of these checkpoint immunotherapy approaches in certain settings, specifically here in cutaneous squamous cell carcinoma. Moreover, they describe clinical response in neoadjuvant setting as 50% for PD-1 monotherapy and 61% for the combination and I really think that this is really ready for prime time.  With the study published in the New England Journal last year and these data now, I really think the field needs to start moving towards the use of perioperative anti-PD-1 with or without ipilimumab as a standard approach. And I think it's the case that even the NCCN and ASCO and various guideline societies are going to start acknowledging that this ought to be considered for most patients who are facing difficult surgical operations for continuous squamous cell carcinoma. Dr. Diwakar Davar: So, Jason, you bring up a fascinating point, which is the appearance of this in guidelines. So this is undoubtedly extraordinarily good data. It's confirmatory, the pathologic response rates in many ways paradoxically low. You'd expect something about 50% or so. But the reason it's low is because 10% of patients who actually benefited didn't undergo surgery. So really the degree of benefit is tremendous. It's about 50% to 60%. So the fascinating thing in the setting that we'd have is if one is going to try to get the drug FDA-approved, what we now have is the conventional setting in which one needs a definitive endpoint. And at least we know that pathological response rate is not a definitive endpoint in the context of melanoma or, for that matter, cutaneous squamous cell carcinoma. The only setting in which it is a regulatory endpoint is a non-small cell lung cancer or triple-negative breast cancer. But recently there's been some very exciting data from another PD-1 inhibitor called dostarlimab in a trial done by your former colleague Dr. Luis Diaz when he demonstrated a dramatic result of dostarlimab in the context of perioperative rectal cancer where it is micro-satellite high wherein the standard of care is typically very disfiguring abdominal perineal resection.    So in the context of some of our listeners who might be thinking a little bit about how this pertains to regulatory approval, what are your thoughts about the paradigm of avoiding highly disfiguring surgery relating to what was seen in the rectal cancer discussion to what we're now seeing with perioperative therapy in the context of cutaneous squamous cell carcinoma?  Dr. Jason Luke: I think it's a very important question. And the easy out for diseases that have a pattern of progression that is metastasis is to use event-free survival which can include both the pre-surgical and the post-surgical period in terms of looking for whether or not the cancer comes back. And that works for diseases potentially like lung cancer, like you said, maybe melanoma. In cutaneous squamous cell carcinoma, however, that's not probably going to work because this tends to be a locally invasive and less of a metastatic disease. So here then, we really need to have sort of organization across patient advocacy, dermatology, medical oncology to come up with what the most appropriate considerations are going to be for evaluating that long-term benefit because I think we need a tangible result that we can show the FDA. Everyone is really impressed by these results, and I think that next step is to craft this into a way that we have a measurable output that we can then go to them with and say bless this so that all of our patients can get this kind of treatment. Dr. Diwakar Davar: Really great discussion, Jason. And I think this is going to be an area of particular interest going forward, given both the number of trials that have been conducted in this space and also the role of the very interesting regulatory paradigm that has now been set initially at least with the rectal cancer that is microsatellite high and now potentially we will see with cutaneous squamous cell carcinoma.   And so the final abstract that we have selected for you is Abstract 9511. And this is a trial that was conducted by a mutual colleague, Dr. Ryan Sullivan, and his colleagues. And it's essentially a trial of looking at targeted therapy with or without navitoclax in BRAF mutant melanoma patients. And part of the reason to highlight this, it's very interesting preclinical data supporting the addition of navitoclax, b but also a great example of an early trial that came through the CTEP portfolio. And so Jason, can you tell us about why this is exciting and how we might contextualize the addition of navitoclax to the targeted therapy backbone?   Dr. Jason Luke: Sure. So listeners will be quite aware of targeting mutant BRAF as a therapeutic strategy across oncology that was really initially pioneered in melanoma with the development of vemurafenib as the first selective BRAF inhibitor. But the field, of course, moved eventually to BRAF and MEK combinations across essentially all settings. We know that dabrafenib and trametinib are now approved pan-cancer for anywhere we find a BRAF V600e mutation. In the context of melanoma, looking at mechanisms of resistance, we observed that they were quite heterogeneous with reactivation of elements of the mitogen-activated protein kinase pathway, the MAPK pathway. But also there were metabolic changes in the cancer cells themselves which could drive resistance and were downstream of some of those reactivation signaling points. So one of those is the induction of anti-apoptotic machinery in the cell. So activation of BCL-2 or Bcl-xL to try to save those melanoma cells when they were under stress by blockade with BRAF and MEK inhibitors. And that observation was made now about a decade ago or more. And that raised the possibility that repurposing a drug that was being used actually in the chemo malignancy space might be useful in augmenting targeted therapy. And that's where we come in with the navitoclax as a BH3-mimetic that can actually knock down those antiapoptotic proteins, BCL-2 Bcl-xL. And so that was the context for this initially phase I clinical trial of combining navitoclax with the dabrafenib and trametinib.  And those data supported the safety of doing that and moved to this study, which was a randomized phase 2 study of that triplet regiment versus the dabrafenib and trametinib alone. And so this study started quite a long time ago, before the sort of initiation or widespread use of anti-PD-1 antibodies. And so it had to kind of undergo some various iterations throughout its course but eventually has now read out. And it had two primary endpoints, with one being focused on improving the complete response rate for targeted therapy because that's been associated with long-term outcomes as well as to look at the maximum tumor shrinkage of patients within this trial and of course to look at other endpoints like response rate, progression-free survival, et cetera.  About half the patients who participated in the trial had prior immune checkpoint blockade and they were actually distributed evenly across the two arms. So we think that probably won't impact on the outcomes. And what was observed in the clinical trial was that in fact, the triplet did improve the complete response rate for targeted therapy. So navitoclax plus dabrafenib and trametinib had a complete response rate of 20% versus dabrafenib and trametinib alone being at 15%. Both of them had an overall response rate in the 80% range, with slightly higher for the triplet at 84% versus 80% for the double-edged standard therapy. There was also a suggestion that there may be a disproportionate benefit for the triplet actually in patients with smaller baseline tumors. And we know that the efficacy of targeted therapy is more pronounced in the lower-volume disease state.   And so overall, when we look at this without really adding much toxicity, I think this is an intriguing place to look at further drug development. BRAF and MEK inhibition has been a backbone therapy in Melanoma for a long time, but we really haven't been able to move past it or augment it in any real way because of the heterogeneity of treatment resistance. And here, by going after metabolic changes, we perhaps might have the opportunity to enhance our targeted therapy somewhat further. And so we'll look forward to further results investigating this regimen in subsequent clinical trials. Dr. Diwakar Davar: Fantastic discussion, Jason. So these are all great insights. As you've heard, we've now discussed a couple of key abstracts covering major topics that will be presented, major themes of the malignancy space at ASCO 2023, including the addition of a lactate inhibitor to checkpoint in both a randomized large phase 3 trial and a smaller phase 2 trial, the context of targeted-therapy in melanoma making another forerun in the post-3c setting. And two very interesting studies I have looked at, checkpoint inhibitor therapy in the context of cutaneous squamous cell carcinoma and Merkel cell carcinoma, addressing themes that are of huge importance going forward, including the role of perioperative therapy in squam and the addition of a CTLA-4 inhibitor in Merkel. These oral abstracts are all going to be presented at the 2023 ASCO Annual Meeting. We look forward to seeing you there.  So, thank you Jason for taking the time to join us and for highlighting these important advances in immunotherapy. And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures:  Dr. Diwakar Davar:  Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:  Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Mitch Moffit is one half of AsapSCIENCE aka one of most successful YouTube channels ever. It took him a decade to truly believe that YouTube was his job. Brought to you By: The Sonar Network https://thesonarnetwork.com/

Emmy Award-winning Newsmax host Lidia Curanaj joins us to discuss how transgenderism is becoming more mainstream on social media accounts often viewed by children. Next senior research fellow at the Heritage Foundation Robert Moffit reveals how Democrats on Capitol Hill are planning to sunset Medicare in its current form. Then, former Fox Business and CNBC anchor Dennis Kneale explains the flaws in the bailout following the collapse of Silicon Valley Bank. Finally your calls in open phones across America. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ashley, from United Way, and Craig Dillon are joined by Jenny Moffit. Listen to the full episode to hear all about the Salvation Army Food Pantry and the Salvation Army Summer Camps.

January 11, 2022 - Donna Firman & Jenny Moffit

Craig is joined by his new cohost, Ashley Bender, from United Way Manitowoc County. Their first guest is Lt. Jenny Moffit with Salvation Army.

Bob Moffit of the Heritage Foundation discusses why Congress needs to do an investigation on the origin of COVID.

In this episode, Kimberly Moffit shares her TikTok journey and what she learned to get a million subscribers. Find out what are the Key Things you should do to grow your account on the platform! TIME-STAMPED SHOW NOTES: [00:00] - Kimberly Moffit's thesis on The Emotional Psychology of Entrepreneurs [01:50] -  What Kimberly Moffit Learned from her Youtube Journey [02:46] - Why Kimberly Moffit thinks TikTok is the Future [03:50] - Content Creation's Quality vs Frequency [05:17] - 3 Key Things You Should Do to Grow Your TikTok To 1M Subs [05:40] - 1. What is important to your audience? [06:50] - 2. Why does your expression matter? [07:34] - 3. How to meet your audience's needs? Leave Some Feedback:   What should I talk about next? Who should I interview? Please let me know on Twitter or in the comments below. Did you enjoy this episode? If so, please leave a short review here Subscribe to Leveling Up on iTunes Get the non-iTunes RSS Feed   Connect with Eric Siu:    Growth Everywhere Single Grain Leveling Up Eric Siu on Twitter Eric Siu on Instagram

With the Melbourne MCTI Summit only weeks away, in this episode, Dr. Preston Cline and MCTI's Director of down-under, Harry Moffitt, prime the audience for some of the subject matter that will be covered at the summit – themed this year around Navigating Change. The MCT community is home to the oldest institutions on earth – military, medical, fire and emergency, police – and in the modern age, all are grappling with the issue of change. How to prepare for change, how to manage it, and how to make it an ongoing practice. During the summit, the audience will be discussing and sharing how change management has been done well in MCTs and share some of the challenges of attempting to enact change in our institutions who are often hampered by longstanding, and sometimes dated, traditions, standards, and stories. In this relaxed, informal chat between Preston and Harry, they discussEmpowering agents of change and empowering zealots.The rise of the enabler.Standards, asking are they all still fit for purpose?New approaches to training and development.And some observations from their Guinness tasting adventure across the US and UK earlier this year.

When Hayden Moffit was born, he was diagnosed with a severe case of cerebral palsy. His parents were told that his future was grim and that he would never leave the hospital. Hayden did leave the hospital and went on to live for over two years. His mother, Rochelle, says God showed his grace and mercy through Hayden's life and did many miracles that kept them going.  Today on Connections, Rochelle shares Hayden's story.  See omnystudio.com/listener for privacy information.

Deborah Moffitt is the experiencer behind the acclaimed novel A Deadly Haunting, which drew upon the frightening experiences she and her family endured at the hands of “Mr. Entity,” their unseen tormentor. Vastly intelligent and destructive, this demon wrought havoc in their lives and home, resulting in a daily battle to maintain their sanity. After 25 years Deborah decided to tell her story, detailing what went on in her family's home during the six year period of nightmare in which “Mr. Entity” plagued them. Deborah's new book Unwelcomed is a purely nonfictional account of what she and her family experienced. Going into more detail of the paranormal phenomena she witnessed, Unwelcomed gives the reader a first-person perspective into the daily torment the Moffitts struggled through in their quest for relief. Many luminaries assisted in their quest, including Ed and Lorraine Warren, Brian Hurst, Kerry Gaynor, and dozens more in the years the entity plagued them.For all the best of the Paranormal / Parapsychology radio programming and features, visit www.xzbn.net.

On this week's episode of Unleashing YOUR Great Work, we are going VIRAL! Leading relationship expert, TikTok sensation, and former pop star, Dr. Kimberly Moffit takes us along on her Great Work journey.Starting as a musician at a young age and then transitioning to a career in Counseling Psychology, Dr. Moffit reveals that much of her life has been about learning, “What do people want to know about?” With social media, she loves to share funny and relatable tips and tricks and with therapy, we can explore the extended version. Join us as we discuss: 02:04 Dr. Kimberly's great work.04:39 How Dr. Kimberly got started with viral content.06:49 How to create viral content that's very relatable.09:22 The challenges of being a YouTuber - Deal with haters online.13:06 The message behind the message.16:37 How Dr. Kimberly acknowledges all types of relationships in her contents22:58 The biggest challenges and biggest lessons learned in transitioning from being a musician to being a psychotherapist. 26:44 Find the right, build that mission and achieve that mission together. 28:17 You have to stay on your own plane, you're always going to be one step ahead of anyone copying you.32:37 Dr. Kimberly's Northstar - Where does she hope to head over the long term?About the Guest:Dr. Kimberly Moffit is a leading relationship expert who has studied the ins and outs of romance and has the answers to love's toughest questions. With over 2M followers on social media, Kimberly's her relationship advice is garnered from the latest research brought to life in fun and relatable tips.Kimberly achieved her Doctoral degree in Psychology and has appeared as a relationship expert on all over the media and television. She is also the founder of KMA Therapy with 5 in-person counselling locations in Toronto and a new location opening in New York City in fall 2022.TikTok: @ask_kimberlyLinks: www.kmatherapy.comAbout the Host:Dr. Amanda Crowell is a cognitive psychologist, speaker, podcaster, author of Great Work, and the creator of the Great Work Journals. Amanda's TEDx talk: Three Reasons You Aren't Doing What You Say You Will Do has received more than a million views and has been featured on TED's Ideas blog and TED Shorts. Her ideas have also been featured on NPR, Al Jazeera, The Wall Street Journal, Quartz, and Thrive Global. Amanda lives in New Jersey with her husband, two adorable kids, and a remarkable newfiepoo named Ruthie. She spends her days educating future teachers, coaching accidental entrepreneurs, and speaking about how to make progress on Great Work to colleges and corporate teams. To book Dr. Crowell to speak or inquire about coaching, check out amandacrowell.com or email amanda@amandacrowell.com. Website: https://amandacrowell.com/Book: https://www.amazon.com/Great-Work-Amanda-J-Crowell/dp/1737374196Podcast: amandacrowell.com/podcastIG: https://www.instagram.com/aj_crowellLinked In: https://www.linkedin.com/in/dr-amanda-crowell-51188130/Thanks for listening!Thanks so much for listening to the Unleash Your Great Work Podcast! If you enjoyed this edit and think that others could benefit from listening, please share it using the social media buttons on this page.Do you have some feedback or questions about this edit? Leave a comment in the section below!Follow the podcastIf you would like to get automatic updates of new...

A 70-year history of Angus cattle stands behind Moffitt Angus in Iowa. I get to catch up with Craig Moffitt and discuss this offering for October 4th!  

In this week's episode of the Top Strength Cast, Steve chops it up with Leo Cormier on starting Recovery CBD from scratch. All of us have overcome obstacles in life but it's how you overcome them that will stand the test of time. If your aspiring business owner or entrepreneur, then this is one episode you won't want to miss. Big thank you to our sponsors Ocean State Nutrition, Arsenal Athletics, Strength IQ, The Breath Belt, Brothers and Moffit, and Recovery CBD, Do you want to listen to shows built to inspire and educate you to be the strongest you can be? This podcast is a GRIT original and is a part of the strongest podcast network on the planet! Learn more by heading over to www.thegritnetwork.com. Follow us on Social GRIT  Top Strength Project  Steve Tripp

In this week's episode of the Top Strength Cast, Steve flies solo leading up to powerlifting nationals. He goes over his mindset and techniques that he has learned with over ten years of experience in competitive strength sports.  Big thank you to our sponsors Ocean State Nutrition, Arsenal Athletics, Strength IQ, The Breath Belt, Brothers and Moffit, and Recovery CBD, Do you want to listen to shows built to inspire and educate you to be the strongest you can be? This podcast is a GRIT original and is a part of the strongest podcast network on the planet! Learn more by heading over to www.thegritnetwork.com. Follow us on Social GRIT  Top Strength Project  Steve Tripp

Wesley continues his escape from the strange entity that destroyed the camp; Voran worries about his friend; and Moffit pontificates.EARLY ACCESS to podcast episodes, behind-the-scenes bonus videos with the Maeltopia team and more await you on our Patreon!Join us on Discord!Follow us on Twitter at @maeltopiaWant to learn more about the world of Maeltopia? Check out our website!Be sure to like, comment, rate and review us on Apple Podcasts or your favorite podcast platform! We appreciate your support!Credits:Written by Walker KornfeldEdited by Walker KornfeldSound mastering by Steven J. Anzalone--Wesley Morrigan voiced by Steven AnzaloneVoran Gaal voiced by Walker Kornfeld Cyrus Moffit voiced by Steven AnzaloneThe Voice voiced by Steven AnzaloneThe Grimland intro music was created by Steven J. AnzaloneMusic by Wicked Cinema, Blut Own, and Justin Marshall EliasMusic and Sound effects are licensed from third party providers including Envato, Epidemic Sound, Artlist, Soundstripe, Melody Loops, and Music Vine See acast.com/privacy for privacy and opt-out information.

As a record-holding strength athlete in both Strongman and Powerlifting, Steve has over 20 years of authentic under-the-bar experience. What you can expect from this show is Steve and other individuals at the top of their fields offering their insight into all things training and competing in strength sports. It is Steve's goal to denounce the limitless bullshit surrounding the industry while offering a direct, sensible, and authentic approach to becoming the best version of yourself. Big thank you to our sponsors Ocean State Nutrition, Arsenal Athletics, Strength IQ, The Breath Belt, Brothers and Moffit, and Recovery CBD, Do you want to listen to shows built to inspire and educate you to be the strongest you can be? This podcast is a GRIT original and is a part of the strongest podcast network on the planet! Learn more by heading over to www.thegritnetwork.com. Follow us on Social GRIT  Top Strength Project  Steve Tripp

Jon Caldera fill sin for George.  This hour Jon discuss the proposed name change of the Colorado town of Moffit, to...wait for it...Kush.   Yes, it is a drug reference.  Good Idea or Bad Idea?   See omnystudio.com/listener for privacy information.

Jon Caldera fills in for George.  Jon continues the conversation about the town of Moffit, CO thinking about a name change and then talks about new rules from the governing body or Swimming on the issue of transgendered athletes.   See omnystudio.com/listener for privacy information.

WEDNESDAY POD!! Mikie previews the LSU Baseball series versus Arkansas as the Razorbacks come into the series leading the Western division in the SEC. With a series win, the Tigers can overtake the Hogs for first place in the West! LSU Baseball reliever and 6'10" flamethrower Paul Gervase joins the show via video call to discuss his journey to LSU and his transformation from a Division 3 pitcher to JUCO to big-time college baseball in the SEC at LSU! The Godfather of LSU Strength and Conditioning, Tommy Moffitt joins the show to discuss everything from his journey to becoming the top strength coach in the country, what the last two seasons at LSU were like, Joe Burrow, and MORE!!!  

Jon Moffit Returns! Greg welcomed back Pastor and podcast host Jon Moffitt this week. We discussed the tricky verse of James 2 that seem to allude to a work based salvation. We talked about the entire context of James, if these are salvific verses, and how to rightly read through James. Whats the difference between an alive faith and a dead faith? Find out on this episode. Enjoy! http://www.dmwpodcast.com Support the show (https://cash.app/$dmwpodcast)

Pear Bureau Northwest president Kevin Moffitt says the challenges keep coming but the pear industry will focus on its consumers with an online focus.

Pear Bureau Northwest president Kevin Moffitt says the challenges keep coming but the pear industry will focus on its consumers with an online focus.

 Author and homeschool pioneer Sam Blumenfeld appears as a guest on "The Great Education Struggle hosted by Issac Moffit.  This show originates on WBCQ The Planet.  Please visit the Sam Blumenfeld Achives:  https://campconstitution.net/sam-blumenfeld-archive/ 

On this week's episode we travelled into space with a young Khary Payton and James Madio, who are on a trek to the icy moon of Europa to investigate new life forms possibly discovered by the filthy rich and NASA hating Moffit industries. However, like all space adventures, things don't quite go as planned. Join us as we discuss 2016's Astronaut: The Last Push by Eric Hayden, in which we talk through one man's struggle with loneliness, the intricacies of travel in outer space and a debate over the best type of reconstituted poop food.

Real Talk with Rima Live Ep. 17 with Jamie MoffitNow live

Check out clips of some of the more interesting interviews from over the past few years on the Hammer Down Racing Report featuring Dr. Jerry Punch, Kenny Wallace, Hailie Deegan, Ryan Wichman with Rusty Schlenk and many more.

September 30, 2021 - Sgt. Jenny Moffit, Salvation Army

What the heck's a Kryomek? Venerable wargamer David Moffit helps us answer this question, and more like "Was Kryomek a good game?" and "Do Kryomek's taste like chicken?" on this week's episode. Also, Mr. Moffit discusses his Dark Age Immortals community event. Come for aliens, stay for the dead games! Useful Links Scotia Grendel Website: Current owners of Kryomek, with the rules as free PDFs available for download. Kryomek Space Time Interstice: Small, but passionate, Facebook group for Kryomek players. Community Events Dark Age After Dark @ DragonFall 2021: October 23rd in Lake Geneva, WI

Colin is a world class Alpinist who has achieved many incredible first Ascents all over the world. We talk about his introduction to the mountains as a kid and how progressed into the Alpinist that he is today. Colin gives insights into how he sets his ambitious goals, talks about why he enjoys climbing solo, the head space that this requires and his wonderful philosophy of Adventure vs Sport. Later in the episode we get into his gear nerd side and the relationship he has with food. Here is a short selection of Colin's most notable ascents:Torre Traverse (Aguja Standhardt, Punta Herron, Torre Egger, Cerro Torre), first ascent (2008), first one-day ascent (2016), and first reverse traverse (2015).Infinite Spur (Sultana, Alaska), first solo ascent and speed record (2016).Aguja Standhardt (2010) and Torre Egger (2016), first solo ascent of each.North Buttress (Begguya, Alaska), first solo ascent and speed record (2017).The Entropy Wall (Mt. Moffit, Alaska), first ascent (2006).